Supplementary Financial Information (Unaudited)

Selected financial information for the quarterly periods noted is as follows (in thousands, except per share amounts):



	Quarters Ended
2018 ^{(1) (2)}	March 31		June 30			September 30		December 31

Net revenue	$	275,189	$	413,787		$	476,487	$	497,528
Gross profit	144,595		178,295			200,105		193,408
Net income (loss)	51,652		(250,090		)	17,465		(20,330		)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	—		(19,104		)	6,952		(8,768		)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders:
Class A and Class B-1 basic	—		(0.15		)	0.05		(0.07		)
Class A and Class B-1 diluted	$	—	$	(0.15	)	$	0.05	$	(0.07	)

	Quarters Ended
2017 ⁽²⁾	March 31		June 30			September 30		December 31

Net revenue	$	225,681	$	259,871		$	254,733	$	293,369
Gross profit	116,016		123,733			135,013		151,416
Net income	42,261		37,748			27,122		62,194
Net income attributable to Amneal Pharmaceuticals, Inc.	—		—			—		—
Net income per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders:
Class A and Class B-1 basic	—		—			—		—
Class A and Class B-1 diluted	$	—	$	—		$	—	$	—

⁽¹⁾ Basic and diluted net income (loss) per share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted net income (loss) per share amounts may not equal annual basic and diluted net income (loss) per share amounts.

⁽²⁾ On May 4, 2018, Impax and Amneal combined the generics and specialty pharmaceutical business of Impax with the generic drug development and manufacturing business of Amneal to create the Company as a new generics and specialty pharmaceutical company. Prior quarters have not been revised as a result of the Combination. Therefore, current year results, and balances, may not be comparable to prior years as the current year includes the impact of the Combination from May 4, 2018. For further details on the Combination, see Note 1. Nature of Operations and Basis of Presentation.